T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Mol Biol Cell - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research
